Flag of the European Union EU Clinical Trials Register Help

Clinical trials for cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44412   clinical trials with a EudraCT protocol, of which   7421   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    34 result(s) found for: cancer. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2007-005725-29 Sponsor Protocol Number: EGF110656 Start Date*: 2008-05-09
    Sponsor Name:GlaxoSmithKline Research and Development
    Full Title: A Phase III Study of ErbB2 Positive Advanced or Metastatic Gastric or Esophageal Or Gastroesophageal Junction Adenocarcinoma Treated with Capecitabine Plus Oxaliplatin with or without Lapatinib
    Medical condition: Subjects with ErbB2-positive advanced or metastatic gastric or oesophageal or gastro-oesophageal junction adenocarcinoma.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001150 Adenocarcinoma gastric LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) IT (Completed) NL (Ongoing) HU (Completed)
    Trial results: View results
    EudraCT Number: 2014-000834-50 Sponsor Protocol Number: MGN1703-C06 Start Date*: 2014-07-09
    Sponsor Name:MOLOGEN AG
    Full Title: IMPALA-Trial: Evaluation of an immunomodulatory maintenance treatment in patients with metastatic colorectal cancer with tumor reduction during induction treatment - A phase III trial
    Medical condition: Metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10010036 Colorectal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Completed) BE (Prematurely Ended) IT (Ongoing) EE (Prematurely Ended) AT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-001841-28 Sponsor Protocol Number: MK-3475-654(INCB24360-305) Start Date*: 2017-11-03
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 2, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Ce...
    Medical condition: Metastatic NSCLC with high PD-L1 expression
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) EE (Completed) ES (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002006-51 Sponsor Protocol Number: MK-3475-975 Start Date*: 2019-12-11
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (K...
    Medical condition: Esophageal Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10015366 Esophageal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) FR (Trial now transitioned) HU (Trial now transitioned) PT (Trial now transitioned) EE (Trial now transitioned) BE (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-003439-18 Sponsor Protocol Number: D0810C00019 Start Date*: 2009-02-20
    Sponsor Name:AstraZeneca AB
    Full Title: Phase II randomised, double blind, multicentre study to assess the efficacy of AZD2281 in the treatment of patients with platinum sensitive serous ovarian cancer following treatment with two or mor...
    Medical condition: platinum sensitive serous ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) DE (Completed) PL (Completed) CZ (Completed) ES (Completed) EE (Completed) FR (Completed) AT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2017-000202-37 Sponsor Protocol Number: AGOOVAR229 Start Date*: 2018-05-04
    Sponsor Name:AGO Research GmbH
    Full Title: Atezolizumab in combination with Bevacizumab and Chemotherapy versus Bevacizumab and Chemotherapy in recurrent ovarian cancer – a randomized Phase III trial
    Medical condition: Efficacy of atezolizumab in combination with non-platinum based chemotherapy and bevacizumab versus the combination of a non-platinum based chemotherapy and bevacizumab in recurrent ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016182 Fallopian tube cancer metastatic PT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) AT (Completed) BE (Completed) ES (Ongoing) NO (Completed) DK (Completed) FI (Completed) LT (Prohibited by CA) EE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004456-30 Sponsor Protocol Number: B9991030 Start Date*: 2018-09-13
    Sponsor Name:Pfizer Inc.
    Full Title: A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB IN COMBINATION WITH CHEMOTHERAPY FOLLOWED BY MAINTENANCE THERAPY OF AVELUMAB IN COMBINATION WITH...
    Medical condition: PREVIOUSLY UNTREATED ADVANCED OVARIAN CANCER
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033130 Ovarian cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SK (Prematurely Ended) CZ (Prematurely Ended) HU (Completed) BE (Completed) GB (GB - no longer in EU/EEA) EE (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000722-38 Sponsor Protocol Number: 1203-GITCG Start Date*: 2015-05-25
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: INtegratioN of trastuzumab, with or without pertuzumab, into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL
    Medical condition: HER-2 positive, resectable gastric cancer
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066896 HER2 positive gastric cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) DE (Completed) BE (Completed) NO (Completed) PT (Completed) GB (GB - no longer in EU/EEA) ES (Completed) NL (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-005241-45 Sponsor Protocol Number: MK3475-061 Start Date*: 2015-04-22
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel in Subjects with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma who Progressed after Fi...
    Medical condition: Gastric or Gastroesophageal Junction Adenocarcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) IT (Completed) EE (Completed) ES (Completed) IE (Completed) DE (Completed) GB (GB - no longer in EU/EEA) DK (Completed) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-000296-36 Sponsor Protocol Number: ZWI-ZW25-301 Start Date*: 2021-11-17
    Sponsor Name:Zymeworks Inc.
    Full Title: A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination with Chemotherapy with or without Tislelizumab in Subjects with HER2-positive Unresectable Locally Advanced or Metastatic Gast...
    Medical condition: Gastroesophageal Adenocarcinoma (GEA)
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004864 10082464 Advanced gastric carcinoma LLT
    21.1 100000004864 10055458 Esophageal adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) PT (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) IE (Trial now transitioned) IT (Trial now transitioned) EE (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004408-76 Sponsor Protocol Number: 3475-585 Start Date*: 2017-08-25
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase III, Randomized, Double-blind, Clinical Trial of Pembrolizumab (MK-3475) plus Chemotherapy (XP or FP) versus Placebo plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subje...
    Medical condition: Gastric or Gastroesophageal Junction Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056267 Gastroesophageal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) LT (Trial now transitioned) EE (Trial now transitioned) LV (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-004450-36 Sponsor Protocol Number: MK-2140-006 Start Date*: 2022-06-10
    Sponsor Name:Merck Sharp & DohmeLLC
    Full Title: A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants with Aggressive and Indolent B-cell Malignancies (...
    Medical condition: Aggressive and Indolent B-cell Malignancies
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061275 Mantle cell lymphoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008976 Chronic lymphocytic leukemia LLT
    24.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10085128 Follicular lymphoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10058728 Richter's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) DE (Trial now transitioned) EE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) CZ (Trial now transitioned) IE (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003397-32 Sponsor Protocol Number: MK2140-004 Start Date*: 2021-12-21
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 2 Open-label Clinical Study to Evaluate the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Medical condition: Treatment of participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) PL (Trial now transitioned) NO (Trial now transitioned) EE (Trial now transitioned) CZ (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004023-20 Sponsor Protocol Number: MK-3475-992 Start Date*: 2020-02-27
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Pa...
    Medical condition: Muscle Invasive Bladder Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10022877 Invasive bladder cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) EE (Trial now transitioned) HU (Trial now transitioned) LV (Trial now transitioned) PT (Trial now transitioned) CZ (Trial now transitioned) NL (Trial now transitioned) IE (Completed) DK (Prematurely Ended) PL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-004856-24 Sponsor Protocol Number: AC220-A-U302 Start Date*: 2016-09-02
    Sponsor Name:Daiichi Sankyo, Inc.
    Full Title: A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Continuation Therapy in Subjects 18 t...
    Medical condition: FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) (+) acute myeloid leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) DE (Completed) HU (Completed) ES (Ongoing) RO (Ongoing) BE (Completed) PT (Completed) BG (Completed) HR (Completed) EE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001810-24 Sponsor Protocol Number: BO25323 Start Date*: 2014-12-17
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PROSPECTIVE, OPEN-LABEL, MULTICENTER RANDOMIZED PHASE III TRIAL TO COMPARE THE EFFICACY AND SAFETY OF A COMBINED REGIMEN OF OBINUTUZUMAB AND VENETOCLAX (GDC-0199/ABT 199) VERSUS OBINUTUZUMAB AND ...
    Medical condition: chronic lymphocytic leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) DK (Trial now transitioned) GB (GB - no longer in EU/EEA) EE (Trial now transitioned) AT (Trial now transitioned) BG (Trial now transitioned) ES (Ongoing) HR (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2016-000250-35 Sponsor Protocol Number: WO30070 Start Date*: 2016-06-16
    Sponsor Name:Roche Farma, S.A., que representa en España a F. Hoffmann-La Roche Ltd.
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI?PD-L1 ANTIBODY) IN COMBINATION WITH GEMCITABINE/CARBOPLATIN VERSUS GEMCITABINE/CARBOPLATIN ALONE I...
    Medical condition: Urothelial Carcinoma, locally advanced or metastatic
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) CZ (Completed) EE (Completed) GR (Completed) PL (Completed) SI (Completed) GB (GB - no longer in EU/EEA) FI (Completed) NL (Completed) PT (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000575-27 Sponsor Protocol Number: MK-3475-091-05 Start Date*: 2015-09-17
    Sponsor Name:Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.
    Full Title: A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy...
    Medical condition: Stage IB (T ≥ 4 cm), II and IIIA NSCLC
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Trial now transitioned) SI (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) ES (Ongoing) EE (Trial now transitioned) HU (Trial now transitioned) PT (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned) DK (Trial now transitioned) GR (Trial now transitioned) LV (Trial now transitioned) CZ (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2014-003698-41 Sponsor Protocol Number: MK-3475-048 Start Date*: 2015-02-19
    Sponsor Name:Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co. Inc.
    Full Title: A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
    Medical condition: Recurrent/metastatic head and neck squamous cell carcinoma.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071540 Head and neck cancer metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) EE (Completed) LV (Completed) DK (Completed) FI (Completed) AT (Completed) CZ (Completed) NL (Completed) HU (Completed) ES (Completed) RO (Ongoing) GR (Completed) DE (Completed) IT (Completed) GB (GB - no longer in EU/EEA) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-002605-10 Sponsor Protocol Number: CJDQ443B12301 Start Date*: 2022-04-01
    Sponsor Name:Novartis Pharma AG
    Full Title: KontRASt-02: A randomized, controlled, open label, phase III study evaluating the efficacy and safety of JDQ443 versus docetaxel in previously treated subjects with locally advanced or metastatic K...
    Medical condition: Advanced non-small cell lung cancer harboring the KRAS G12C mutation
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed) HU (Trial now transitioned) ES (Ongoing) NO (Completed) GR (Trial now transitioned) PT (Trial now transitioned) FI (Trial now transitioned) DK (Completed) SI (Trial now transitioned) EE (Completed) IT (Trial now transitioned) PL (Completed) HR (Completed) IS (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Oct 17 05:14:55 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA